Multicenter randomized trial of facilitated percutaneous coronary intervention with low-dose tenecteplase in patients with acute myocardial infarction : the Athens PCI trial
2009 Wiley-Liss, Inc..
OBJECTIVES: To examine the safety and efficacy of low-dose tenecteplase, administered before facilitated percutaneous coronary intervention (PCI) to restore Thrombolysis In Myocardial Infarction (TIMI) grade 2 or 3 blood flow in the infarct related artery (IRA) in patients with ST elevation myocardial infarction (STEMI) scheduled to undergo PCI with a shortest anticipated delay of 30 min.
BACKGROUND: PCI preceded by administration of glycoprotein IIb/IIIa inhibitors, full-dose thrombolytics, or both, is associated with no benefit or a higher incidence of adverse events than PCI alone.
METHODS: Patients with STEMI < 6 hr in duration were randomly assigned to PCI preceded by tenecteplase, 10 mg (facilitated PCI group, n = 143) versus standard PCI (control group, n = 141). All patients received aspirin and unfractionated heparin (70 IU/kg bolus) at time of randomization. Both groups received IIb/IIIa inhibitors in the catheterization laboratory and for at least 20 hr after PCI.
RESULTS: The median door-to-balloon time was 122 min (91-175) in the facilitated PCI versus 120 min (89-175) in the control group. IRA patency on arrival in the catheterization laboratory was 59.5% in the facilitated PCI (24% TIMI-2, 35% TIMI-3), versus 37% in the control (8% TIMI-2, 29% TIMI-3) group (P = 0.0001). During hospitalization, 9 patients (6%) died in the facilitated PCI versus 5 patients (3.5%) in the control group (P = 0.572). A single patient in the facilitated PCI group suffered a non-fatal ischemic stroke.
CONCLUSIONS: Facilitated PCI with low-dose tenecteplase in patients presenting with STEMI was associated with a high IRA patency rate before PCI.
| Errataetall: |
CommentIn: Catheter Cardiovasc Interv. 2009 Sep 1;74(3):406-7. - PMID 19681117 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2009 |
|---|---|
| Erschienen: |
2009 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:74 |
|---|---|
| Enthalten in: |
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions - 74(2009), 3 vom: 01. Sept., Seite 398-405 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kanakakis, John [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 29.10.2009 Date Revised 01.12.2018 published: Print CommentIn: Catheter Cardiovasc Interv. 2009 Sep 1;74(3):406-7. - PMID 19681117 Citation Status MEDLINE |
|---|
| doi: |
10.1002/ccd.22009 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM187763577 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM187763577 | ||
| 003 | DE-627 | ||
| 005 | 20231223180710.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231223s2009 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ccd.22009 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0626.xml |
| 035 | |a (DE-627)NLM187763577 | ||
| 035 | |a (NLM)19360864 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kanakakis, John |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Multicenter randomized trial of facilitated percutaneous coronary intervention with low-dose tenecteplase in patients with acute myocardial infarction |b the Athens PCI trial |
| 264 | 1 | |c 2009 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.10.2009 | ||
| 500 | |a Date Revised 01.12.2018 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: Catheter Cardiovasc Interv. 2009 Sep 1;74(3):406-7. - PMID 19681117 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a 2009 Wiley-Liss, Inc. | ||
| 520 | |a OBJECTIVES: To examine the safety and efficacy of low-dose tenecteplase, administered before facilitated percutaneous coronary intervention (PCI) to restore Thrombolysis In Myocardial Infarction (TIMI) grade 2 or 3 blood flow in the infarct related artery (IRA) in patients with ST elevation myocardial infarction (STEMI) scheduled to undergo PCI with a shortest anticipated delay of 30 min | ||
| 520 | |a BACKGROUND: PCI preceded by administration of glycoprotein IIb/IIIa inhibitors, full-dose thrombolytics, or both, is associated with no benefit or a higher incidence of adverse events than PCI alone | ||
| 520 | |a METHODS: Patients with STEMI < 6 hr in duration were randomly assigned to PCI preceded by tenecteplase, 10 mg (facilitated PCI group, n = 143) versus standard PCI (control group, n = 141). All patients received aspirin and unfractionated heparin (70 IU/kg bolus) at time of randomization. Both groups received IIb/IIIa inhibitors in the catheterization laboratory and for at least 20 hr after PCI | ||
| 520 | |a RESULTS: The median door-to-balloon time was 122 min (91-175) in the facilitated PCI versus 120 min (89-175) in the control group. IRA patency on arrival in the catheterization laboratory was 59.5% in the facilitated PCI (24% TIMI-2, 35% TIMI-3), versus 37% in the control (8% TIMI-2, 29% TIMI-3) group (P = 0.0001). During hospitalization, 9 patients (6%) died in the facilitated PCI versus 5 patients (3.5%) in the control group (P = 0.572). A single patient in the facilitated PCI group suffered a non-fatal ischemic stroke | ||
| 520 | |a CONCLUSIONS: Facilitated PCI with low-dose tenecteplase in patients presenting with STEMI was associated with a high IRA patency rate before PCI | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 650 | 7 | |a Fibrinolytic Agents |2 NLM | |
| 650 | 7 | |a Platelet Aggregation Inhibitors |2 NLM | |
| 650 | 7 | |a Platelet Glycoprotein GPIIb-IIIa Complex |2 NLM | |
| 650 | 7 | |a Heparin |2 NLM | |
| 650 | 7 | |a 9005-49-6 |2 NLM | |
| 650 | 7 | |a Tissue Plasminogen Activator |2 NLM | |
| 650 | 7 | |a EC 3.4.21.68 |2 NLM | |
| 650 | 7 | |a Aspirin |2 NLM | |
| 650 | 7 | |a R16CO5Y76E |2 NLM | |
| 650 | 7 | |a Tenecteplase |2 NLM | |
| 650 | 7 | |a WGD229O42W |2 NLM | |
| 700 | 1 | |a Nanas, John N |e verfasserin |4 aut | |
| 700 | 1 | |a Tsagalou, Eleftheria P |e verfasserin |4 aut | |
| 700 | 1 | |a Maroulidis, George D |e verfasserin |4 aut | |
| 700 | 1 | |a Drakos, Stavros G |e verfasserin |4 aut | |
| 700 | 1 | |a Ntalianis, Argirios S |e verfasserin |4 aut | |
| 700 | 1 | |a Tzoumele, Panagiotis |e verfasserin |4 aut | |
| 700 | 1 | |a Skoumbourdis, Emmanuel |e verfasserin |4 aut | |
| 700 | 1 | |a Charbis, Panagiotis |e verfasserin |4 aut | |
| 700 | 1 | |a Rokas, Stylianos |e verfasserin |4 aut | |
| 700 | 1 | |a Anastasiou-Nana, Maria |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions |d 1999 |g 74(2009), 3 vom: 01. Sept., Seite 398-405 |w (DE-627)NLM101487487 |x 1522-726X |7 nnns |
| 773 | 1 | 8 | |g volume:74 |g year:2009 |g number:3 |g day:01 |g month:09 |g pages:398-405 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/ccd.22009 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 74 |j 2009 |e 3 |b 01 |c 09 |h 398-405 | ||